Table 4 Unadjusted odds of completing M6 in 1011 participants by baseline patient characteristics and other variables
Patient characteristics | Univariate analysis | ||
|---|---|---|---|
ORa | 95% CIb | P | |
Gender | |||
Female | — | — | |
Male | 0.93 | 0.72, 1.20 | 0.587 |
Education | |||
College or lower | — | — | |
High school or lower | 0.86 | 0.67, 1.11 | 0.252 |
Marital status | |||
Married/living as married | — | — | |
Single/divorced/widowed/separated | 0.83 | 0.64, 1.06 | 0.140 |
Age | |||
< 55 | — | — | |
≥ 55 | 1.21 | 0.94, 1.57 | 0.135 |
Used cannabis for any reason 5 or more times in the last 12 months | |||
No | — | — | |
Yes | 0.93 | 0.72, 1.20 | 0.579 |
Primary illness or medical condition you currently treat with medical cannabis | |||
Pain | — | — | |
Mental health issues | 0.79 | 0.52, 1.20 | 0.275 |
Insomnia | 0.98 | 0.54, 1.77 | 0.942 |
Other | 0.94 | 0.56, 1.57 | 0.805 |
Use of opioid | |||
N | — | — | |
Y | 0.69 | 0.52, 0.92 | 0.011 |
Use of non-opioid pain medications | |||
N | — | — | |
Y | 1.13 | 0.83, 1.53 | 0.439 |
Use of benzodiazepine | |||
N | — | — | |
Y | 1.32 | 0.81, 2.18 | 0.269 |
Use of antidepressant | |||
N | — | — | |
Y | 1.52 | 1.09, 2.13 | 0.014 |
Use of anti-seizure | |||
N | — | — | |
Y | 1.68 | 1.19, 2.36 | 0.003 |
Opioid—dose per day (DDD) | |||
> 0, < 0.57 | — | — | |
≥ 0.57 | 0.67 | 0.38, 1.17 | 0.157 |
Non-opioid pain medications—dose per day (DDD) | |||
> 0, < 0.43 | — | — | |
≥ 0.43 | 0.72 | 0.39, 1.33 | 0.289 |
Benzodiazepine—dose per day (DDD) | |||
> 0, < 0.38 | — | — | |
≥ 0.38 | 1.54 | 0.54, 4.42 | 0.423 |
Antidepressant—dose per day (DDD) | |||
> 0, < 1 | — | — | |
≥ 1 | 1.50 | 0.68, 3.31 | 0.316 |
Anti-seizure—dose per day (DDD) | |||
> 0, < 0.5 | — | — | |
≥ 0.5 | 0.82 | 0.39, 1.72 | 0.60 |
WHOQOL—physical health (baseline) | |||
< 36 | — | — | |
≥ 36 | 1 | 0.78, 1.28 | 0.981 |
WHOQOL—psychological (baseline) | |||
< 54 | — | — | |
≥ 54 | 1.33 | 1.03, 1.71 | 0.028 |
WHOQOL—social relationships (baseline) | |||
< 58 | — | — | |
≥ 58 | 1.23 | 0.95, 1.60 | 0.114 |
WHOQOL—environment (baseline) | |||
< 66 | — | — | |
≥ 66 | 1.15 | 0.89, 1.47 | 0.289 |
Cannabis use per week (g) | |||
< 5 | — | — | |
≥ 5 | 1.06 | 0.83, 1.36 | 0.645 |
Frequency of cannabis use per week | |||
< 14 | — | — | |
≥ 14 | 1.11 | 0.87, 1.44 | 0.401 |
Currently using Tilray extract products | |||
N | — | — | |
Y | 0.91 | 0.70, 1.18 | 0.479 |
Preferred type of cannabis | |||
CBD | — | — | |
THC | 1.29 | 0.94, 1.78 | 0.113 |
No preference | 1.56 | 1.16, 2.10 | 0.004 |
Primary method of use | |||
Inhaled | — | — | |
Orally ingested | 0.72 | 0.56, 0.93 | 0.012 |
Enrollment period | |||
Enrolled prior to 17 April 2018 (M6 would be pre-legalization) | — | — | |
Enrolled between 17 April and 15 July 2018 (M6 would be post legalization) | 0.32 | 0.22, 0.46 | < 0.001 |